Apidel announces the signature of an agreement to collaborate with DNDi (Drugs for Neglected Diseases initiative) on the preclinical development of a topical treatment for Cutaneous Leishmaniasis, a neglected disease affecting between 0.7 to 1.2 million people worldwide. A promising drug candidate will be tested with Apidel’s proprietary drug delivery technology ApidSOL™. The press release is available here.